Street Calls of the Week
Investing.com -- Veeva Systems Inc Class A (NYSE:VEEV) stock rose 2% on Thursday following the announcement of a long-term partnership with OpenEvidence to jointly create and market an AI platform called Open Vista.
The collaboration aims to leverage artificial intelligence to increase patient access to clinical trials, accelerate drug discovery, and improve understanding and adoption of existing approved medicines. The partnership combines Veeva’s expertise in life sciences software with OpenEvidence’s AI-powered clinical decision support system, which is currently used by more than 40% of U.S. physicians.
"We are very excited about our long-term partnership with OpenEvidence as we enter the AI chapter in life sciences," said Veeva CEO Peter Gassner. "With Open Vista our aim is to help life sciences companies accelerate the development of effective new treatments, enable more patients to participate in clinical trials, and advance the understanding and adoption of existing medicines for better patient outcomes."
Daniel Nadler, CEO of OpenEvidence, highlighted the potential impact of the partnership, particularly for patients with serious illnesses who have exhausted standard treatment options. He noted that clinical trials often represent the most promising form of healthcare for these patients.
The companies expect to release the first Open Vista product offerings in 2026, suggesting a multi-year development timeline for the AI platform.
Veeva Systems provides cloud-based software solutions for the global life sciences industry, while OpenEvidence specializes in AI-powered clinical decision support tools for healthcare providers.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.